FDA Type A Meeting Scheduled for Tabelecleucel BLA Following Complete Response Letter
Summary
Atara Biotherapeutics announced that a Type A meeting with the FDA has been scheduled to discuss the Complete Response Letter for its tabelecleucel BLA, a key step towards potential resubmission.
Key Events
-
FDA Type A Meeting Scheduled
Atara Biotherapeutics announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Complete Response Letter (CRL) for the EBVALLO™ Biologics License Application (BLA) issued on January 9, 2026.
-
Addressing CRL Points for Resubmission
The company's partner, Pierre Fabre Pharmaceuticals, with Atara's support, will meet with the FDA to collaboratively address the points from the CRL and enable a resubmission with additional efficacy data.
-
Regulatory Update Anticipated
Atara's President and CEO, Cokey Nguyen, expressed optimism about gaining clarity on a path forward for BLA resubmission and anticipates providing a further regulatory update in the second quarter of 2026.
Analysis
Atara Biotherapeutics announced that a Type A meeting with the FDA has been scheduled to discuss the Complete Response Letter (CRL) for its tabelecleucel (tab-cel) Biologics License Application (BLA). This follows the company's previous disclosure on March 3, 2026, regarding the request for such a meeting. The scheduling of this meeting is a critical step forward for the company and its partner, Pierre Fabre Pharmaceuticals, as it provides a defined path to address the FDA's concerns and potentially resubmit the BLA. For a small biotech, progress in regulatory discussions after a CRL is a significant de-risking event, offering clarity on the path to market.
At the time of this filing, ATRA was trading at $6.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.9M. The 52-week trading range was $3.92 to $19.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.